EU antitrust charge for Servier, Teva, others over generics
BRUSSELS, July 30
BRUSSELS, July 30 (Reuters) - EU antitrust regulators charged French drugmaker Servier, Israel's Teva and four other firms on Monday with blocking the entry of generic perindopril medicine to market, its second major case against a key element of business in the pharmaceutical industry.
"At this stage, the (European) Commission takes the view that the patent settlement agreements concluded by Servier with Niche/Unichem, Matrix (today Mylan Laboratories Limited), Teva, Krka and Lupin, as well as Servier's acquisition of key competing technologies were aimed at delaying or preventing the market entry of cheap generic versions of perindopril, in violation of EU antitrust rules," the EU watchdog said in a statement.
- Ukraine accuses Russia of "undisguised aggression" as rebels advance |
- Disruptive Hong Kong protests loom after China rules out democracy |
- Syrian army, rebels fight on Golan where peacekeepers held |
- NATO to create new 'spearhead' force to respond to crises
- Investors look past Ukraine, focus on ECB